In HCC, clinical trials with nivolumab (CheckMate 040) showed that the response rate was 18.6% with PD-L1 expression of less than 1%, and there was no significant difference depending on PD-L1 expression [154]. This evidence concerns the gene CD274 and hepatocellular carcinoma.